Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2025-12-25 @ 3:37 AM
NCT ID:
NCT00829205
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed, CD20+, diffuse large B-cell lymphoma (DLBCL) according to WHO lymphoma classification
* Histological transformation of a previously known indolent lymphoma allowed
* Biopsy-proven DLBCL arising from an indolent lymphoma not diagnosed previously allowed
* Disease in first relapse after complete remission, partial response (PR), or less than a PR after first-line of treatment
* No primary CNS lymphoma
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Life expectancy \> 3 months
* Serum creatinine \< 150 μmol/L
* Serum bilirubin \< 35 μmol/L
* Transaminases \< 2.5 times upper limit of normal (unless attributed to lymphoma)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No contraindication to any of the drugs contained in the immunochemotherapy regimen
* No other malignancy within the past 2 years, except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
* No other serious active disease that, in the opinion of the investigator, would preclude the patient from having conventional chemotherapy
* No HIV positivity
* No medical or psychiatric conditions that compromise the patient's ability to give informed consent
PRIOR CONCURRENT THERAPY:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00829205
Study Brief:
Protocol Section:
NCT00829205